(Q37861212)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463188%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

review article

1 reference

title

Brentuximab vedotin for the treatment of CD30+ lymphomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463188%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463188%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Kelley V Foyil

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463188%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463188%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463188%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463188%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463188%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

475-485

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463188%20AND%20SRC:MED&resulttype=core&format=json

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

27 January 2020

cites work

1 reference

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience

21 January 2018

1 reference

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

21 January 2018

1 reference

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

21 January 2018

1 reference

Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience

21 January 2018

1 reference

Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.

21 January 2018

1 reference

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

21 January 2018

1 reference

CD30 in normal and neoplastic cells.

21 January 2018

1 reference

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

21 January 2018

1 reference

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

21 January 2018

1 reference

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

21 January 2018

1 reference

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

21 January 2018

1 reference

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

21 January 2018

1 reference

Histone deacetylase inhibitors in lymphoma

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.

21 January 2018

1 reference

A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

21 January 2018

1 reference

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma

21 January 2018

1 reference

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

21 January 2018

1 reference

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

21 January 2018

1 reference

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

21 January 2018

1 reference

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

21 January 2018

1 reference

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

21 January 2018

1 reference

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

21 January 2018

1 reference

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

21 January 2018

1 reference

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics

21 January 2018

1 reference

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

21 January 2018

1 reference

TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.

21 January 2018

1 reference

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

21 January 2018

1 reference

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

21 January 2018

1 reference

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.11.15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21463188%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference